Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;55(5):416-21.
doi: 10.2176/nmc.ra.2014-0394. Epub 2015 Apr 28.

The present indication and future of deep brain stimulation

Affiliations
Review

The present indication and future of deep brain stimulation

Kenji Sugiyama et al. Neurol Med Chir (Tokyo). 2015.

Abstract

The use of electrical stimulation to treat pain in human disease dates back to ancient Rome or Greece. Modern deep brain stimulation (DBS) was initially applied for pain treatment in the 1960s, and was later used to treat movement disorders in the 1990s. After recognition of DBS as a therapy for central nervous system (CNS) circuit disorders, DBS use showed drastic increase in terms of adaptability to disease and the patient's population. More than 100,000 patients have received DBS therapy worldwide. The established indications for DBS are Parkinson's disease, tremor, and dystonia, whereas global indications of DBS expanded to other neuronal diseases or disorders such as neuropathic pain, epilepsy, and tinnitus. DBS is also experimentally used to manage cognitive disorders and psychiatric diseases such as major depression, obsessive-compulsive disorder (OCD), Tourette's syndrome, and eating disorders. The importance of ethics and conflicts surrounding the regulation and freedom of choice associated with the application of DBS therapy for new diseases or disorders is increasing. These debates are centered on the use of DBS to treat new diseases and disorders as well as its potential to enhance ability in normal healthy individuals. Here we present three issues that need to be addressed in the future: (1) elucidation of the mechanisms of DBS, (2) development of new DBS methods, and (3) miniaturization of the DBS system. With the use of DBS, functional neurosurgery entered into the new era that man can manage and control the brain circuit to treat intractable neuronal diseases and disorders.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Disclosure

All the authors declared their conflicts of interest (COI) to The Japan Neurosurgical Society (JNS) office. There are no COI with any person or organization affiliated with this work.

Figures

Fig. 1
Fig. 1
Two technologies of DBS under development. A: Closed loop DBS system with a sensor in the apparatus, and a stimulator, which is activated only when the sensor detects abnormal brain signals. B: Multidirectional DBS leads where three or four electrodes surround around the lead axis. One can select not only the depth but also the direction of each current flow. DBS: deep brain stimulation.
Fig. 2
Fig. 2
Neuroendoscopic deep brain stimulation. In this method, electrodes will be placed on the ventricular wall using a neuroendoscope. There are multiple areas surrounding the ventricular wall, which are already used as the target of functional neurosurgery, or which could be used for functional stimulation.

References

    1. Finger S: Treatment and therapies: from antiquity through the seventeenth century, from 1700 to World War I, in Origins of Neuroscience. London, Oxford University Press, 1994, pp 415– 440
    1. Hariz MI, Blomstedt P, Zrinzo L: Deep brain stimulation between 1947 and 1987: the untold story. Neurosurg Focus 29: E1, 2010. - PubMed
    1. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J: Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 50: 344– 346, 1987. - PubMed
    1. Hassler R, Riechert T, Mundinger F, Umbach W, Ganglberger JA: Physiological observations in stereotaxic operations in extrapyramidal motor disturbances. Brain 83: 337– 350, 1960. - PubMed
    1. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ: A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546– 4550, 1983. - PMC - PubMed